WQ5 Stock Overview
Operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing, and halting the ageing process, and reducing the incidence of age-related diseases with increase in health span in the United Kingdom and Belgium. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Genflow Biosciences plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.018 |
| 52 Week High | UK£0.036 |
| 52 Week Low | UK£0.012 |
| Beta | 2.35 |
| 11 Month Change | -7.50% |
| 3 Month Change | -24.49% |
| 1 Year Change | -5.13% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -86.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| WQ5 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -7.5% | 0.8% | 0.8% |
| 1Y | -5.1% | -18.3% | 8.6% |
Return vs Industry: WQ5 exceeded the German Biotechs industry which returned -16.9% over the past year.
Return vs Market: WQ5 underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| WQ5 volatility | |
|---|---|
| WQ5 Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: WQ5's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: WQ5's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 5 | Eric Leire | genflowbio.com |
Genflow Biosciences plc, together with its subsidiaries, operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing, and halting the ageing process, and reducing the incidence of age-related diseases with increase in health span in the United Kingdom and Belgium. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use.
Genflow Biosciences plc Fundamentals Summary
| WQ5 fundamental statistics | |
|---|---|
| Market cap | €7.25m |
| Earnings (TTM) | -€1.84m |
| Revenue (TTM) | €716.84k |
10.1x
P/S Ratio-4.0x
P/E RatioIs WQ5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WQ5 income statement (TTM) | |
|---|---|
| Revenue | UK£598.04k |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£598.04k |
| Other Expenses | UK£2.13m |
| Earnings | -UK£1.53m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0044 |
| Gross Margin | 100.00% |
| Net Profit Margin | -256.07% |
| Debt/Equity Ratio | 0% |
How did WQ5 perform over the long term?
See historical performance and comparison